Literature DB >> 12903805

New approaches to the prevention and eradication of rabies.

Bernhard Dietzschold1, Milosz Faber, Matthias J Schnell.   

Abstract

Despite significant progress in improving the pre- and postexposure prophylaxis of human rabies, the development of better and more cost-effective vaccines and antiviral therapeutics remains a major goal for the treatment of human rabies, the control of animal rabies and particularly for the eradication of rabies virus reservoirs in terrestrial wildlife. In this review, we discuss the structural requirements for an effective rabies vaccine, as well as new strategies currently in use for the development of safer and more potent rabies vaccines for rabies prophylaxis and eradication. Finally, we discuss new immune therapeutics aimed at replacing the conventional administration of antirabies immunoglobulin used in rabies post-exposure prophylaxis in humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12903805     DOI: 10.1586/14760584.2.3.399

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  15 in total

1.  A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity.

Authors:  Milosz Faber; Marie-Luise Faber; Amy Papaneri; Michael Bette; Eberhard Weihe; Bernhard Dietzschold; Matthias J Schnell
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

2.  A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies.

Authors:  Milosz Faber; Elaine W Lamirande; Anjeanette Roberts; Amy B Rice; Hilary Koprowski; Bernhard Dietzschold; Matthias J Schnell
Journal:  J Gen Virol       Date:  2005-05       Impact factor: 3.891

Review 3.  The application of reverse genetics technology in the study of rabies virus (RV) pathogenesis and for the development of novel RV vaccines.

Authors:  Matthias J Schnell; Gene S Tan; Bernhard Dietzschold
Journal:  J Neurovirol       Date:  2005-02       Impact factor: 2.643

Review 4.  The cell biology of rabies virus: using stealth to reach the brain.

Authors:  Matthias J Schnell; James P McGettigan; Christoph Wirblich; Amy Papaneri
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

5.  Concepts in the pathogenesis of rabies.

Authors:  Bernhard Dietzschold; Jianwei Li; Milosz Faber; Matthias Schnell
Journal:  Future Virol       Date:  2008-09       Impact factor: 1.831

6.  Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity.

Authors:  Elizabeth J Faul; Celestine N Wanjalla; James P McGettigan; Matthias J Schnell
Journal:  Virology       Date:  2008-10-21       Impact factor: 3.616

7.  Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain.

Authors:  Byoung-Shik Shim; Konrad Stadler; Huan Huu Nguyen; Cheol-Heui Yun; Dong Wook Kim; Jun Chang; Cecil Czerkinsky; Man Ki Song
Journal:  Virol J       Date:  2012-09-21       Impact factor: 4.099

8.  Immunogenicity studies in carnivores using a rabies virus construct with a site-directed deletion in the phosphoprotein.

Authors:  Ad Vos; Karl-Klaus Conzelmann; Stefan Finke; Thomas Müller; Jens Teifke; Anthony R Fooks; Andreas Neubert
Journal:  Adv Prev Med       Date:  2011-09-21

9.  Human rabies cluster following badger bites, People's Republic of China.

Authors:  Gong Zhenyu; Wang Zhen; Chen Enfu; He Fan; Lin Junfen; Li Yixin; Ding Gangqiang; R E Fontaine
Journal:  Emerg Infect Dis       Date:  2007-12       Impact factor: 6.883

10.  Development in Immunoprophylaxis against Rabies for Animals and Humans.

Authors:  Sukdeb Nandi; Manoj Kumar
Journal:  Avicenna J Med Biotechnol       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.